IFT22

Across TCGA pan-cancer cohorts, IFT22 RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of IFT22’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where IFT22 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types IFT22 is over-expressed in tumor, although a few such as KICH and THCA show the opposite, repressed pattern.

COAD, KICH, and LIHC are the cancer types where IFT22 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in IFT22 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	Female	II,III,IV	+1.303	<.001	11	view →
KICH	Female	II,III,IV	−2.150	<.001	9	view →
LIHC	Female	II,III,IV	+1.191	<.001	9	view →
HNSC	Male	III,IV	+0.860	<.001	7	view →
KIRP	All	II,III,IV	+0.453	<.001	7	view →
BRCA	All	III,IV	+0.775	<.001	6	view →
CHOL	Female	All	+2.966	<.001	5	view →
LUAD	All	All	+0.285	.004	4	view →
ESCA	All	All	+1.238	.005	2	view →
READ	Male	All	+0.953	.023	2	view →
THCA	Male	All	−0.235	.021	2	view →
BLCA	Male	IV	−0.704	.022	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

IFT22–COAD

Open the COAD breakdown →